Canadian Cancer Trials Group Bulletins

Trial Management Group


Trial Closed to Accrual

Canadian Cancer Trials Group OV.18 (MRC ICON6) -- A Randomized Trial of Concurrent Cediranib [AZD2171] (with Platinum-Based Chemotherapy) and Maintenance Cediranib in Women with Platinum-Sensitive Relapsed Ovarian Cancer -- was closed to accrual on 14 December 2011.

Following the negative results in bowel, lung cancer and glioma studies, AstraZeneca, the manufacturer of cediranib, has made a business decision to stop the development of cediranib. AstraZeneca has informed the MRC CTU (the lead group for OV.18) that, although the production of cediranib will be discontinued, sufficient supplies exist to treat all patients currently on the ICON6/OV.18 study according to protocol-mandated guidelines.

Thanks to all participating centres, staff and patients for their participation and efforts on this trial.